XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
07 nov. 2024 07h30 HE
|
XOMA Corporation
Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s...
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
22 oct. 2024 08h00 HE
|
XOMA Corporation
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
23 sept. 2024 06h30 HE
|
XOMA Corporation
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
XOMA Royalty Declares Quarterly Preferred Stock Dividends
23 sept. 2024 05h30 HE
|
XOMA Corporation
October 2024 Dividends on Perpetual Preferred Shares
XOMA Royalty to Present at Upcoming Investor Conferences in September
04 sept. 2024 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the...
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
13 août 2024 07h30 HE
|
XOMA Corporation
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the...
XOMA Declares Quarterly Preferred Stock Dividends
20 juin 2024 07h30 HE
|
XOMA Corporation
July 2024 Dividends
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
12 juin 2024 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta...
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
14 mai 2024 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C....
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
09 mai 2024 07h30 HE
|
XOMA Corporation
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...